A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

NCT03019406 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Glycogen Storage Disease Type II-Pompe's Disease

Interventions

DRUG: Avalglucosidase alfa (GZ402666)
DRUG: Alglucosidase alfa (GZ419829)

Sponsor

Genzyme, a Sanofi Company